Green Cross Labcell Joins US$1.8 bln Deal to Develop Cancer Drug

SEOUL, Jan. 29 (Korea Bizwire) — A subsidiary of South Korean pharmaceutical firm Green Cross Corp. said Friday it has participated in a partnership deal worth US$1.8 billion to develop natural killer (NK) cell therapies to treat cancer. Under the collaboration, Green Cross LabCell will co-develop three kinds of chimeric antigen receptor (CAR) NK cell [...]